Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MIN 117

Drug Profile

MIN 117

Alternative Names: MIN-117; Wf-516; WF516

Latest Information Update: 24 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Minerva Neurosciences
  • Class Analgesics; Antidepressants; Oxadiazoles; Piperidines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine plasma membrane transport protein antagonists; Serotonin 1A receptor antagonists; Serotonin 2A receptor antagonists; Serotonin plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pain
  • Discontinued Major depressive disorder

Most Recent Events

  • 24 Feb 2021 MIN 117 is still in phase II trials for Major depressive disorder in Bulgaria, Finland, Poland and USA (Minerva Neurosciences pipeline, February 2021)
  • 31 Dec 2020 Discontinued - Phase-II for Major depressive disorder in Latvia, Bulgaria, USA, Finland, Poland (PO)
  • 18 Dec 2019 Top-line safety and efficacy data from a phase IIb trial in Major depressive disorder released by Minerva Neurosciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top